The US FDA may have to create a post-marketing plan to address concerns about off-label use of oral testosterone should it approve either Clarus Therapeutics Inc.'s Jatenzo (testosterone undecanoate) or Lipocine Inc.'s Tlando (testosterone undecanoate). The plan could include a cardiovascular outcomes trial or a risk management plan, members of the Bone, Reproductive and Urologic Drugs Advisory Committee suggested during their Jan. 9-10 review of the products.
Oral Testosterones Might Use REMS, CV Post-Market Study To Win Approval
US FDA advisory committee worries about off-label use of Lipocine's Tlando and Clarus' Jatenzo.
More from US FDA Performance Tracker
• By
March features nearly 20 user fee goal dates, including a crowd of novel candidates for crowded areas like hemophilia, heart disease and urinary tract infections, as well as the potentially first therapies for a rare eye disease and hyperphagia of Prader-Willi syndrome.
• By
The US FDA approval of new meningococcal and chikungunya vaccines arrived in time for the 26-28 February meeting of the CDC’s Advisory Committee On Immunization Practices, if political developments allow.
• By
The US FDA is receiving more requests for regenerative medicine advanced therapy designation and granting more of them, according to recently reported agency data.
• By
Top areas for potential 2025 approvals were shaped by R&D focused on increasingly tightly targeted therapies, including the eight new candidates to join the still-burgeoning kinase inhibitor class and RNA interference, as well as many varieties of antibodies.